ELSEVIER

Colloids and Surfaces B: Biointerfaces 16 (1999) 333

COLLOIDS AND SURFACES B

Author Index

Akaike, T., 271
Akutsu, T., 225
Alakhov, V., 111
Allen, C., 3
Altinok, H., 71
Aoyagi, T., 193, 235
Attwood, D., 71

Batrakova, E., 111, 289
Bazile, D., 171
Bonadio, J., 279
Booth, C., 71
Bronich, T.K., 241
Bronitch, T., 111
Burt, H.M., 159

Cammas-Marion, S., 205
Carlisle, R.C., 259
Clark Jr., C.G., 43

Davis, S.S., 145

Eisenberg, A., 3, 241
Embree, L., 159

Ferdous, A., 271
Fisher, K.D., 251
Fukushima, S., 225

Garnett, M.C., 145
Goldstein, S.A., 279
Gorry, P.A., 71
Govender, T., 145

Han Bae, Y., 183
Havredaki, V., 71
Huang, H., 43
Hunter, W.L., 159

Illum, L., 145

Jeong, B., 183

Kabanov, A., 111, 289
Kabanov, A.V., 1, 241, 319
Kabanov, V.A., 27, 241
Kataoka, K., 1, 133, 205, 225, 235
Kato, M., 133
Kelarakis, A., 71
Klinski, E., 111
Kohori, F., 193
Kowalewski, T., 43
Kwon, G.S., 215

Labhasetwar, V., 279
Levy, R.J., 279
Li, S., 111
Li, Y., 215

Machida, M., 225
Maruyama, A., 271
Mashiba, H., 225
Maysinger, D., 3
Menger, F.M., 27
Miller, D.W., 319

Nagarajan, R., 53
Nagasaki, Y., 133
Nehls, A., 241
Nixon, S.K., 71

Ohnishi, Y.-i., 271
Okamoto, K., 225
Okano, T., 193, 205, 225, 235

Pietrzynski, G., 111
Plard, J.-P., 171

Rakhnyanskaya, A.A., 27
Rapoport, N., 91
Read, M.L., 259
Riley, T., 145

Sakai, K., 193
Sakurai, Y., 193, 225, 235
Seymour, L.W., 251, 259
Shimizu, K., 225
Stolnik, S., 145
Sugi, K.-i., 235

Tanaka, S., 225
Thurmond II, K.B., 43
Toleikis, P., 159
Torchilin, V.P., 303
Torigoe, H., 271

Venne, A., 111
Vinogradov, S., 289

Wan Kim, S., 183
Ward, C.M., 251
Watanabe, H., 271
Wolfert, M.A., 259
Wooley, K.L., 43

Xiong, C.D., 145

Yamamoto, Y., 133
Yamato, M., 193
Yaroslavov, A.A., 27
Yaroslavova, E.G., 27
Yokoyama, M., 193, 225

Zhang, X., 159

PII: S0927-7765(99)00124-1

ELSEVIER

Colloids and Surfaces B: Biointerfaces 16 (1999) 335–336

COLLOIDS AND SURFACES B

Subject Index

Adriamycin, 193, 225
Adriamycin dimer, 225
Albumin, 251
All-*trans*-retinoic acid, 241
Anticancer drug, 225
Antisense oligonucleotide, 289
Associates, 235

Biocompatibility, 159
Biodegradable, 183
Biodistribution, 159
Block, 43
Block copolymer, 183
Block copolymer micelles, 3, 53
Block copolymers, 111, 241
Blood–brain barriers, 319
Blood–cerebral spinal fluid barriers, 319

Central nervous system, 319
Coagulation, 171
Colloidal stability, 145
Conjugate, 215
Conjugation of charged peptides, 133
Copolymer, 43
Copolymer micelles, 133
Counterion condensation, 271
Cross-linked, 43
Cytotoxicity, 193

Dextran, 271
Diagnostic imaging, 303
Diblock copolymer, 159, 215
Diblock copolymers, 71
DNA, 251, 259, 279
Doxorubicin, 91, 111, 241
Drug carriers, 205
Drug delivery, 91
Drug delivery systems, 279
Drug targeting, 225
Duplex DNA, 271

Electron paramagnetic resonance, 91

Fluorescence spectroscopy, 91

Gelation, 71
Gene therapy, 259, 279
Graft copolymer, 271

Hydrogel, 289
Hydrogen bonding, 235
Hydrophobic drugs, 3

Integrin, 259
Interpolyelectrolyte complex, 271
Intravenous toxicity, 171

Methotrexate, 215
Micellar solubilization, 159
Micelle, 183
Micelles, 205, 303
Micelle stabilization, 91
Micellisation, 71
Micellization, 91
Morphology of micelles, 3
Multidrug resistance, 289
Multidrug resistant tumours, 111

Nanoparticles, 145, 171, 289
Nanospheres, 43

Oleic acid, 241
Oxyethylene/oxypropylene, 71

Paclitaxel, 159, 241
PEG-PLGA-PEG, 183
PEO–PPO–PEO triblock copolymers, 53
Peptide delivery, 235
PLA–PEG, 145
Pluronic, 91, 111
Pluronic® block copolymers, 53
Polycations, 27
Poly(D,L-lactic acid), 171
Poly(D,L-lactide), 193
Poly(ethylene glycol), 289

PII: S0927-7765(99)00125-3

Polyethylene glycol, 171
Poly(ethylene glycol)–poly(D,L-lactide), 133
poly(ethylene glycol)-poly(L-aspartic acid) copolymer, 235
Polyethyleneimine, Drug delivery, 289
Poly(ethylene oxide), 215
Poly(L-lysine), 251, 259, 271
Polymer, 279
Polymeric drug carrier, 235
Polymeric drug delivery systems, 319
Polymeric micelle, 225
Polymeric micelles, 91, 193, 215, 303
Polymers, 27
Polymer-surfactant complexes, 241
Poly(*N*-isopropylacrylamide), 193

Rat, 171
RGD, 259
Ruboxyl, 91

Safety, 171
Shell, 43
Site-specific, 205
Solubilizate-induced aggregate shape transitions, 53
Solubilization in micelles, 53
Solubilization of hydrocarbons, 53
Spherical, cylindrical and lamellar aggregates, 53
Sustained action, 279

Thermal response, 193
Thermodynamics of solubilization, 53
Thermosensitive, 183
Transfection, 259
Triplex DNA, 271
Turbidometry, 251

Ultrasound, 91

Vasopressin, 235
Vesicles, 27